---
title: "Stryker pays $400 million for a rival robot as Intuitive files a gut endoscope with no revenue date"
description: "Intuitive has asked the FDA to clear a flexible robotic endoscope for the gastrointestinal tract, a market with no revenue date. The same week, Stryker paid $400 million for US rights to a rival robot, weeks before Intuitive's October 20 earnings test."
publisher: "The Inference"
section: "Health"
published: 2026-10-16T21:36:32.556Z
modified: 2026-10-16T21:36:32.556Z
canonical: https://theinference.org/article/stryker-pays-400-million-for-a-rival-robot-as-intuitive-files-a-gut-endoscope-with-no-revenue-date
language: en
keywords: "Intuitive Surgical, Stryker, Medtronic, Surgical Robots, FDA, Health Care"
---

# Stryker pays $400 million for a rival robot as Intuitive files a gut endoscope with no revenue date

> Intuitive has asked the FDA to clear a flexible robotic endoscope for the gastrointestinal tract, a market with no revenue date. The same week, Stryker paid $400 million for US rights to a rival robot, weeks before Intuitive's October 20 earnings test.

## An endoscope for the gut, a filing with no revenue date

[Intuitive Surgical](https://theinference.org/markets/companies/intuitive-surgical), the Sunnyvale maker of the da Vinci surgical robot, [submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance](https://ava.fund/news/intuitive-surgical-submits-next-generation-gi-robotic-endoscope-to-fda-13102026), in news dated October 13 [1]. The system is built to work inside the gastrointestinal tract, and chief executive David Rosa says it combines what the company learned from da Vinci and its Ion lung-biopsy robot [2]. Management's own framing is blunt: early stage, no near-term revenue [2].

## The rivals spent the same week buying in

[Stryker](https://theinference.org/markets/companies/stryker), the US device giant, put about $400 million into CMR Surgical of Cambridge for exclusive US rights to sell the Versius soft-tissue robot, plus an option to acquire the company [3]. [Medtronic](https://theinference.org/markets/companies/medtronic) announced a robotics partnership with Cornerstone Robotics, [an investment MassDevice pegs at $700 million](https://www.massdevice.com/stryker-dives-into-soft-tissue-robotics-with-400m-play-for-cmr-surgicals-versius/), and raised its fiscal 2027 organic growth outlook to 7.25-7.75% after a $9.76 billion quarter [3][4]. [Johnson & Johnson](https://theinference.org/markets/companies/johnson-and-johnson) [won FDA authorization for its Ottava robot in July](https://www.businesswire.com/news/home/20260717254564/en/Johnson-Johnson-Receives-FDA-Market-Authorization-in-the-U.S.-for-its-OTTAVA-Robotic-Surgical-System) [5]. In India, SS Innovations' installed base hit 238 systems, up 42%, on procedures up 79% [1]. All of it points at the soft-tissue market where MassDevice calls Intuitive the industry leader [3].

## The annuity the challengers are circling

Intuitive's economics are razors and blades. Some 11,710 da Vinci systems were installed as of June 30, and every procedure consumes instruments and accessories [6]. [Second-quarter procedures grew 16%, revenue reached $2.89 billion, up 18.4%, and net profit rose to $818.1 million](https://www.ad-hoc-news.de/boerse/news/corporate-news/intuitive-surgical-stock-gains-as-q2-procedure-growth-and-da-vinci/70105334) [6][7]. That annuity carries a $148.5 billion market value at 47.8 times trailing earnings, with [the stock far below its 52-week high of $603.88](https://theinference.org/article/three-fronts-one-earnings-date-intuitive-s-robot-monopoly-gets-tested) [7].

![A da Vinci surgical system with its instrument arms over an operating table and a surgeon console at right](https://storage.googleapis.com/theinference-public/img/0a8a5b4532f121f3.jpg)

*The franchise the challengers are circling: 11,710 da Vinci systems were installed as of June 30, and every procedure is a fresh sale of instruments and accessories. (Cmglee)*

*Chart: **Quarterly revenue is up two-thirds in three years, to $2.89 billion** Line chart of Intuitive Surgical quarterly revenue from Q3 2023 to Q2 2026, rising from $1.74 billion to $2.89 billion*

*Quarterly revenue is up two-thirds in three years, to $2.89 billion [8][9]*

## What October 20 prices

The crack is demand at home. US procedure growth slowed to 12% in the second quarter while international grew 20%, China pricing is a headwind, and [Wall Street expects Q3 revenue of $2.88 billion, 15% growth](https://finance.yahoo.com/healthcare/articles/isrg-ahead-q3-earnings-procedure-111000894.html), a step down from 18.4% [8]. Against that, Intuitive beat estimates four straight quarters, and raised its 2026 adjusted gross-margin outlook to 68-69% [8]. The report lands after the close on October 20 [8]. Watch procedures and placements. The challengers paid hundreds of millions for options on this market. Intuitive filed for one and attached no revenue date at all.

*Chart: **Worldwide procedures still grew 16%, but the US engine slowed to 12%** Column chart of Intuitive Surgical procedure growth in the June 2026 quarter: worldwide 16 percent, United States 12 percent, international 20 percent*

*Year-over-year procedure growth in the quarter ended June 30, 2026. Sources: ad-hoc-news, second-quarter procedure growth and installed base (6); Zacks, Q3 earnings preview with the regional split (8). [6][8]*

## Takeaway

Rivals spent the week paying hundreds of millions for options on Intuitive's soft-tissue robotics market, while Intuitive filed for a GI endoscope it attached no revenue date to; October 20 results test whether US procedure growth holds.

## Sources

1. [Ava Advisor, "Intuitive Surgical Submits Next-Generation GI Robotic Endoscope to FDA," 13 October 2026](https://ava.fund/news/intuitive-surgical-submits-next-generation-gi-robotic-endoscope-to-fda-13102026)
2. [Zacks via Yahoo Finance, "ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters," 13 October 2026](https://finance.yahoo.com/healthcare/articles/isrg-expanding-beyond-surgery-heres-164000201.html)
3. [MassDevice, Conor Hale, "Stryker dives into soft-tissue robotics with $400M play for CMR Surgical's Versius," 13 October 2026](https://www.massdevice.com/stryker-dives-into-soft-tissue-robotics-with-400m-play-for-cmr-surgicals-versius/)
4. [Medtronic plc press release via PR Newswire/Morningstar, "Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance," 1 September 2026](https://www.morningstar.com/news/pr-newswire/20260901cg37273/medtronic-reports-first-quarter-fiscal-2027-results-delivers-broad-based-portfolio-performance-and-raises-fiscal-2027-guidance)
5. [Johnson & Johnson via Business Wire, "Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA Robotic Surgical System," 22 July 2026](https://www.businesswire.com/news/home/20260717254564/en/Johnson-Johnson-Receives-FDA-Market-Authorization-in-the-U.S.-for-its-OTTAVA-Robotic-Surgical-System)
6. [ad-hoc-news, "Intuitive Surgical stock gains as Q2 procedure growth and da Vinci installs impress," 15 September 2026](https://www.ad-hoc-news.de/boerse/news/corporate-news/intuitive-surgical-stock-gains-as-q2-procedure-growth-and-da-vinci/70105334)
7. [ad-hoc-news, "Intuitive Surgical stock has results due October 20, 2026," 16 October 2026](https://www.ad-hoc-news.de/boerse/news/corporate-news/intuitive-surgical-stock-has-results-due-october-20-2026/70330649)
8. [Zacks via Yahoo Finance, "ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?," 16 October 2026](https://finance.yahoo.com/healthcare/articles/isrg-ahead-q3-earnings-procedure-111000894.html)
9. [Intuitive Surgical, quarterly revenue from its SEC filings (Q3 2023 to Q2 2026), retrieved 16 October 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001035267)


---

Stryker pays $400 million for a rival robot as Intuitive files a gut endoscope with no revenue date — The Inference. Canonical: https://theinference.org/article/stryker-pays-400-million-for-a-rival-robot-as-intuitive-files-a-gut-endoscope-with-no-revenue-date